Can eosinophil to monocyte ratio be a new marker for recurrence in graves' disease?

başer, özden; Köseoğlu, Derya; Çatak, Merve

doi:10.5455/medscience.2022.07.167

Can eosinophil to monocyte ratio be a new marker for recurrence in graves' disease?

Özden Özdemir BAŞER, (Yozgat Şehir Hastanesi, Endokrinoloji ve Metabolizma Anabilim Dalı, Yozgat, Türkiye)

Derya KÖSEOĞLU, (Hitit Üniversitesi, Erol Alkan Eğitim ve Araştırma Hastanesi, Endokrinoloji ve Metabolizma Anabilim Dalı, Çorum, Türkiye)

Merve ÇATAK (Gaziosmanpaşa Üniversitesi, Endokrinoloji ve Metabolizma Bölümü, Tokat, Türkiye)

Medicine Science

2 0

Yıl: 2022 Cilt: 11 Sayı: 4 Sayfa Aralığı: 1436 - 1440 Metin Dili: İngilizce DOI: 10.5455/medscience.2022.07.167 İndeks Tarihi: 08-05-2023

Can eosinophil to monocyte ratio be a new marker for recurrence in graves' disease?

Öz:

Prognostic parameters are crucial in the choice of treatment in Graves' disease (GD), thus,these parameters may not be easily achievable in all situations. However he- matological parameters is important in inflammation and easy to obtain. In this study we aimed to elucidate whether these parameters could determine the prognosis in patients with Graves Disease. This retrospective analysis consisted of 114 individuals with a diagnosed with GD. The enrolled patients were treated with anti-thyroid drugs for an average of 14 months and the mean follow-up period after treatment discontinuation was 17.4 months. After the follow-up period subjects have been segmented to 2 groups as: Group 1 relapsed (n:61) and Group 2 non-relapsed (n:53). The neutrophil to lymphocyte ratio (NLR) of the relapsing individual was statistically significantly higher compared to other group, while the eosinophil to monocytes ratio (EMR) was lower. In the multiregression analysis, both parameters were found to be independent risk factors in predicting relapse [(OR=3.1, p:0.026 for NLR) (OR=1.5, p<0.001 for EMR)]. In addition, a value of 0.17 EMR had 70% sensitivity and 80% specificity in determining recurrence. EMR was found to be an independent predictor of prognosis with high specificity. The calculation of EMR before initiating treatment could provide beneficial outcomes for the choice of treatment in patients with GD.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Ross DS, Burch HB, Cooper DS, et al. 2016 american thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26:1343-421.
2. Kahaly GJ, Bartalena L, Hegedüs L, et al. 2018 european thyroid association guideline for the management of graves’ hyperthyroidism. European Thyroid J. 2018;7:167-86.
3. Chittawar S, Dutta D, Qureshi Z, et al. Neutrophil-lymphocyte ratio is a novel reliable predictor of nephropathy, retinopathy, and coronary artery disease in indians with type-2 diabetes. Indian J Endocrinol Metabolism. 2017;21:864.
4. Shi L, Qin X, Wang H, et al.Elevated neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio and decreased platelet-to-lymphocyte ratio are associated with poor prognosis in multiple myeloma. Oncotarget. 2017;8:18792.
5. Kyritsi EMA, Yiakoumis X, Pangalis GA, et al. High frequency of thyroid disorders in patients presenting with neutropenia to an outpatient hematology clinic strobe-compliant article. Medicine. 2015;94.
6. Kim M, Kim BH, Jang MH, et al. High neutrophil-to-lymphocyte ratio is associated with relapse in graves' disease after antithyroid drug therapy. Endocrine. 2020;67:406-11.
7. Vita R, Di Bari F, Perelli S, et al.Thyroid vascularization is an important ultrasonographic parameter in untreated graves’ disease patients. J Clin Translational Endocrinol. 2019;15:65-9.
8. Bartalena L, Baldeschi L, Boboridis K, et al. The 2016 european thyroid association/european group on graves' orbitopathy guidelines for the management of graves' orbitopathy. European Thyroid J. 2016;5:9-26.
9. Shabana W, Peeters E, De Maeseneer M. Measuring thyroid gland volume: Should we change the correction factor? Am J Roentgenol. 2006;186:234-6.
10. Uzzaman A, Cho SH. Classification of hypersensitivity reactions. Allergy Asthma Proc. 2012;33:96-9.
11. Paschke R, Brückner N, Eck T, et al. Regional stimulation of thyroid epithelial cells in graves' disease by lymphocytic aggregates and plasma cells. European J Endocrinol. 1991;125:459-65.
12. Mills KH. Regulatory t cells: Friend or foe in immunity to infection? Nature Rev Immunol. 2004;4:841-55.
13. Rapoport B, McLachlan SM. Graves' hyperthyroidism is antibody-mediated but is predominantly a th1-type cytokine disease. J Clin Endocrinol Metabolism. 2014;99:4060-1.
14. Turan E. Evaluation of neutrophil-to-lymphocyte ratio and hematologic parameters in patients with graves' disease. Bratislavske Lekarske Listy. 2019;120:476-80.
15. Taşkaldiran I, Omma T, Önder ÇE, et al. Neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, and platelet-to-lymphocyte ratio in different etiological causes of thyrotoxicosis. Turk J Med Sci. 2019;49:1687-92.
16. Çetı̇ n E, Kamış F, Karakılıç E, et al. Evaluation of the hematologic indices in patients with thyrotoxicosis with distinct etiologies: a case-control study. J Health Sci Med. 2021;4:p.198-202.
17. Kim M, Kim BH, Jang MH, et al. High neutrophil-to-lymphocyte ratio is associated with relapse in graves’ disease after antithyroid drug therapy. Endocrine. 2020;67:406-11.
18. Hidaka Y, Kimura M, Izumi Y, et al. Increased serum concentration of eosinophil-derived neurotoxin in patients with graves' disease. Thyroid. 2003;13:129-32.
19. Jiang Y, Kanaoka Y, Feng C, et al. Cutting edge: Interleukin 4-dependent mast cell proliferation requires autocrine/intracrine cysteinyl leukotriene- induced signaling. J Immunol. 2006;177:2755-9.
20. Jaffe JS, Glaum MC, Raible DG, et al. Human lung mast cell il-5 gene and protein expression: Temporal analysis of upregulation following ige- mediated activation. Am J Respirat Cell Molecular Biol. 1995;13:665-75.
21. Hu Y, Zhou D, Chen J, Shan P. Eosinophil/monocyte ratio combined with serum thyroid hormone for distinguishing graves' disease and subacute thyroiditis. Frontiers Endocrinol. 2020;11:264.

APA	başer ö, Köseoğlu D, Çatak M (2022). Can eosinophil to monocyte ratio be a new marker for recurrence in graves' disease?. , 1436 - 1440. 10.5455/medscience.2022.07.167
Chicago	başer özden,Köseoğlu Derya,Çatak Merve Can eosinophil to monocyte ratio be a new marker for recurrence in graves' disease?. (2022): 1436 - 1440. 10.5455/medscience.2022.07.167
MLA	başer özden,Köseoğlu Derya,Çatak Merve Can eosinophil to monocyte ratio be a new marker for recurrence in graves' disease?. , 2022, ss.1436 - 1440. 10.5455/medscience.2022.07.167
AMA	başer ö,Köseoğlu D,Çatak M Can eosinophil to monocyte ratio be a new marker for recurrence in graves' disease?. . 2022; 1436 - 1440. 10.5455/medscience.2022.07.167
Vancouver	başer ö,Köseoğlu D,Çatak M Can eosinophil to monocyte ratio be a new marker for recurrence in graves' disease?. . 2022; 1436 - 1440. 10.5455/medscience.2022.07.167
IEEE	başer ö,Köseoğlu D,Çatak M "Can eosinophil to monocyte ratio be a new marker for recurrence in graves' disease?." , ss.1436 - 1440, 2022. 10.5455/medscience.2022.07.167
ISNAD	başer, özden vd. "Can eosinophil to monocyte ratio be a new marker for recurrence in graves' disease?". (2022), 1436-1440. https://doi.org/10.5455/medscience.2022.07.167

APA	başer ö, Köseoğlu D, Çatak M (2022). Can eosinophil to monocyte ratio be a new marker for recurrence in graves' disease?. Medicine Science, 11(4), 1436 - 1440. 10.5455/medscience.2022.07.167
Chicago	başer özden,Köseoğlu Derya,Çatak Merve Can eosinophil to monocyte ratio be a new marker for recurrence in graves' disease?. Medicine Science 11, no.4 (2022): 1436 - 1440. 10.5455/medscience.2022.07.167
MLA	başer özden,Köseoğlu Derya,Çatak Merve Can eosinophil to monocyte ratio be a new marker for recurrence in graves' disease?. Medicine Science, vol.11, no.4, 2022, ss.1436 - 1440. 10.5455/medscience.2022.07.167
AMA	başer ö,Köseoğlu D,Çatak M Can eosinophil to monocyte ratio be a new marker for recurrence in graves' disease?. Medicine Science. 2022; 11(4): 1436 - 1440. 10.5455/medscience.2022.07.167
Vancouver	başer ö,Köseoğlu D,Çatak M Can eosinophil to monocyte ratio be a new marker for recurrence in graves' disease?. Medicine Science. 2022; 11(4): 1436 - 1440. 10.5455/medscience.2022.07.167
IEEE	başer ö,Köseoğlu D,Çatak M "Can eosinophil to monocyte ratio be a new marker for recurrence in graves' disease?." Medicine Science, 11, ss.1436 - 1440, 2022. 10.5455/medscience.2022.07.167
ISNAD	başer, özden vd. "Can eosinophil to monocyte ratio be a new marker for recurrence in graves' disease?". Medicine Science 11/4 (2022), 1436-1440. https://doi.org/10.5455/medscience.2022.07.167